Viatris Inc. (VTRS)

Market Cap	14.94B
Revenue (ttm)	15.05B
Net Income (ttm)	-883.30M
Shares Out	1.19B
EPS (ttm)	-0.74
PE Ratio	n/a
Forward PE	5.03
Dividend	$0.48 (3.83%)
Ex-Dividend Date	Nov 22, 2024

Volume	52,542,531
Open	12.21
Previous Close	12.13
Day's Range	12.14 - 12.57
52-Week Range	9.93 - 13.62
Beta	0.95
Analysts	Hold
Price Target	13.67 (+9.19%)
Earnings Date	Nov 7, 2024

About VTRS

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agent...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1961
• Employees: 38,000
• Stock Exchange: NASDAQ
• Ticker Symbol: VTRS
• Website: https://www.viatris.com

Financial Performance

In 2023, Viatris's revenue was $15.43 billion, a decrease of -5.14% compared to the previous year's $16.26 billion. Earnings were $54.70 million, a decrease of -97.37%.

Analyst Forecast

According to 3 analysts, the average rating for VTRS stock is "Hold." The 12-month stock price forecast is $13.67, which is an increase of 9.19% from the latest price.

Price Target

$13.67

(9.19% upside)

Analyst Consensus: Hold